INTRODUCTION
============

In 2012, prostate cancer was the fifth most commonly diagnosed malignancy in Korean men \[[@B1]\]. The incidence of prostate cancer is lower in Korea than in western countries \[[@B2]\]. However, a steady increase has been observed in the prevalence of prostate cancer in Korea during the last decade \[[@B3]\]. Progression of prostate cancer leads to metastasis, and most patients respond to androgen deprivation therapy (ADT). However, patients develop resistance to ADT, and this condition is known as metastatic castration-resistant prostate cancer (mCRPC). Metastatic CRPC is defined by progression of cancer despite the effective lowering of serum testosterone levels to castrate levels \[[@B4]\]. Docetaxel plus prednisone is the current standard of care for mCRPC in Korea, but this therapy has toxic effects and leads to the development of drug resistance \[[@B5]\]. Recent findings have shown that androgen receptor signaling plays an important role in CRPC, which suggests that inhibition of this pathway using non-cytotoxic therapies may confer a survival benefit. The results of the international, randomized, double-blind, phase 3, PREVAIL trial in chemotherapy-naïve men showed that enzalutamide improves overall survival (OS) \[[@B6]\].

Results of the PREVAIL showed that treatment with enzalutamide showed positive outcomes on all secondary endpoints, including the time until the first skeletal-related event (SRE), soft-tissue response rate, time until prostatespecific antigen (PSA) progression, and PSA response rate (≥50% decline), as well as patient-reported outcomes \[[@B6][@B7][@B8][@B9]\]. Enzalutamide was approved in Korea in June 2013 for use in men with CRPC post-chemotherapy based on the results of the AFFIRM trial. In May 2015, the indication was expanded to include men with CRPC regardless of previous exposure to chemotherapy based on results of the PREVAIL trial \[[@B10]\]. This study aimed to evaluate the clinical results of enzalutamide in chemotherapy-naïve mCRPC patients using Korean, multicenter, real-world data and to compare them with the results of the PREVAIL study. In Korea, continuous ADT for mCRPC patients was prohibited until January 2017; subsequently, concurrent ADT was allowed. Thus, we were able to analyze the efficacy of enzalutamide and concurrent ADT in the treatment of patients with chemotherapy-naïve mCRPC. This study will support evidence to the current recommendations for continuing luteinizing hormone-releasing hormone (LHRH) therapy, which can improve the benefits of enzalutamide treatment in patients with chemotherapy-naïve mCRPC.

MATERIALS AND METHODS
=====================

1. Study design and patients
----------------------------

We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 tertiary centers in Korea between 2014 and 2017. The exclusion criteria were previous docetaxel chemotherapy, brain metastasis, or epidural disease. Patients who had already received enzalutamide treatment included in a clinical trial were excluded. Enzalutamide was administered daily at an initial dose of 160 mg, and ADT was administered in a conventional manner. Unlike the PREVAIL trial, our trial did not have stringent eligibility criteria to reflect a real clinical environment. The endpoint of this trial was OS, which was defined as the time from the start of treatment to any cause of death. We followed the protocol mentioned in the PREVAIL trial for the definition of response criteria and endpoints in Prostate Cancer Clinical Trial Working Group 2, Solid Tumor Version 1.1 (RECIST 1.1). For patients with a decreased PSA levels at week 13, the time to PSA progression was defined as the day on which PSA levels increased by more than 25% and the day on which PSA levels increased by at least 2 ng/mL over a minimum of two consecutive days. For patients without a decreased PSA levels at week 13, the day on which PSA levels increased by more than 25% and the day on which a 2 ng/mL increase over baseline levels was recorded was identified as the second consecutive value. Radiographic progression-free survival (rPFS) was defined as the time of initial objective evidence of radiological progression or death. Radiographic progression is defined as the appearance of two or more new lesions according to RECIST 1.1 or on the bone scan for soft tissue disease. SREs are defined as the events that necessitate changes in chemotherapy, such as radiation therapy or bone surgery for the treatment of pathological fractures, spinal cord compression, or bone pain. Advent events (AEs) were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.3.

2. Data collection and statistical analysis
-------------------------------------------

The research data were collected using the Research Electronic Data Capture (REDCap) program designed to support data capture. We performed the chi-square or Mann--Whitney U tests to compare the categorical and continuous variables, respectively, between the two groups. PFS and OS were analyzed using Kaplan--Meier methods and log-rank tests. Univariate and multivariate Cox proportional hazards regression analyses were performed to assess the association between baseline parameters and OS. All p-values correspond to two-sided tests, with p-values \<0.05 considered statistically significant. PSA response summaries were presented as percentages of patients who showed a decrease in PSA levels by more than 50% or 90%, respectively, from baseline to lowest point, and were visualized using waterfall plots. AEs were described as the rate of all grade or grade ≥3 events.

3. Ethical statement
--------------------

This study was approved by the Institutional Review Boards at each participating center (representative IRB: Seoul National University Hospital IRB no. H-1604-099-755). Subjects provided written informed consent, and the study was performed according to the Declaration of Helsinki.

RESULTS
=======

Demographic features and disease characteristics of patients are shown in [Table 1](#T1){ref-type="table"} \[[@B6][@B10]\]. Initial results showed that 81.5% of the patients had Gleason score (GS) ≥8 and 33.3% of the patients had European Cooperative Oncology Group Performance Status (ECOG PS) 0. Eighty-nine patients (44.9%) received concurrent ADT. Median follow-up is 9.4 months (interquartile range, 3.9--13.5 months). The overall mortality rate was 12%. The Kaplan--Meier curves for OS and rPFS are shown in [Fig. 1](#F1){ref-type="fig"}\[[@B6][@B10]\]. Median OS, median rPFS, median time until chemotherapy, median time until first SRE was not reached until our analysis ([Fig. 1](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}) \[[@B6][@B10]\]. Median time until PSA progression was 6 months ([Table 2](#T2){ref-type="table"}) \[[@B6][@B10]\]. After enzalutamide treatment, 35.2% of patients received more than one systemic chemotherapy ([Table 3](#T3){ref-type="table"}) \[[@B6][@B10]\]. The median OS was not achieved and 76.7% of patients were alive at 30 months. In a Kaplan--Meier curve with 95% confidence interval (CI), OS was 0.84 (95% CI, 0.76--0.91) at 12 months and 0.77 (95% CI, 0.67--0.87) at 24 months ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). The results of the univariate Cox proportional hazard analysis for OS showed that concurrent ADT, ECOG PS, and baseline PSA levels were significant predictors of OS ([Table 4](#T4){ref-type="table"}). Results of multivariate analysis showed that enzalutamide and concurrent ADT significantly improved the OS (hazard ratio, 0.346; 95% CI, 0.125--0.958). The median duration of enzalutamide treatment was 5 months, and the incidence of AEs of grade 3 or higher was 1.7% ([Table 5](#T5){ref-type="table"}) \[[@B6][@B10]\]. The Kaplan--Meier curves for OS, PSA PFS, and rPFS after concurrent ADT are shown in [Fig. 2](#F2){ref-type="fig"}. The OS by 2 years was significantly improved with concurrent ADT (84.6% vs. 71.7%, p=0.015). In addition, patients receiving concurrent ADT showed a significant improvement in PSA PFS (8.0 vs. 4.6 months, p=0.008). However, rPFS at 2 years was not different in patients receiving concurrent ADT (71.8% vs. 68.4%, p=0.154). The waterfall plot of the change in PSA levels in patients receiving concurrent ADT is shown in [Fig. 3](#F3){ref-type="fig"}. To compare Korean real-world data with the result of the PREVAIL study, we described data of PREVAIL study in [Table 1](#T1){ref-type="table"}, [Table 2](#T2){ref-type="table"}, [Table 3](#T3){ref-type="table"}, [Table 5](#T5){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"} \[[@B6][@B10]\].

DISCUSSION
==========

The effects of enzalutamide observed in our study with asymptomatic or mildly symptomatic Korean chemotherapy-naïve patients with mCRPC were consistent with those observed in the study population of the PREVAIL trial \[[@B6][@B10]\].

However, the baseline disease characteristics of the subjects in our study were different from those of the subjects in the PREVAIL trial, which may be because of the differences in real clinical practice. A high percentage of Korean patients had a GS of at least 8, which indicates a high disease burden. Our finding was consistent with that observed in the PREVAIL trial in that 50.6% and 81.1% patients receiving enzalutamide among the overall population and in Korean subgroup, respectively, has a GS ≥8 \[[@B10]\]. Some differences were observed in the characteristics of the disease between the real-world Korean patients and the subjects in the PREVAIL trial; these differences may be related to differences in ethnicity. Compared to the overall study population of the PREVAIL trial, a larger proportion of Korean patients had poor PS. A lower proportion of patients in our study had ECOG PS=0 (33.3% vs. 67.0% in the PREVAIL study). In clinical practice, the physicians, patients, and relatives of chemotherapy-naïve patients with mCRPC with poor PS are reluctant to undergo chemotherapy. Therefore, they prefer treatment with enzalutamide despite its high cost before commencing chemotherapy. Thus, this finding may explain why our data showed that a high proportion of Korean patients had poor performance status. Korean patients receiving enzalutamide had a short median time until PSA progression, and poor baseline characteristics and PS may be attributed to this result. In addition to baseline characteristics, concurrent ADT affects the OS. Unlike the patients in the PREVAIL trial, a larger proportion of Korean patients (55%) had did not receive concurrent ADT with enzalutamide in the clinical setting because the Korean medical insurance system prohibited continuous ADT for mCRPC until January 2017. Our results showed that ADT administered concurrently with enzalutamide improved the oncologic outcomes of chemotherapy-naïve patients with mCRPC.

To date, no study has established evidence supporting continuation of LHRH therapy for CRPC \[[@B11]\]. Few studies have investigated the effects of termination of LHRH therapy in patients with CRPC and, therefore, the current European guidelines recommend medical castration \[[@B12]\]. The Korean medical insurance system prohibited continuous ADT for mCRPC because of lack of evidence until January 2017. Continuation of LHRH therapy may cause considerable side effects and unnecessary expenses \[[@B13]\]. Results from previous clinical trials indicate that castration offers only a marginal survival benefit \[[@B14][@B15]\]. Taylor et al. \[[@B14]\] reported the results of a retrospective study, which showed a significant marginal survival benefit for patients continuing an LHRH agonist along with anthracycline, platinum, or ketoconazole treatment for mCRPC. However, a consensus remains to be achieved about the continuation of LHRH treatment. Analysis of 5 Southwest Oncology Group phase II chemotherapy trials conducted in the 1990s failed to show an obvious advantage of continuous ADT in terms of response to cytotoxic chemotherapy or OS in patients with CRPC \[[@B15]\]. The results of another retrospective study of 78 patients failed to show a survival benefit of docetaxel and concurrent ADT in patients with CRPC \[[@B16]\]. However, it could be an underpowered study because of the small number of patients. Lee et al. \[[@B16]\] found that serum testosterone levels did not recover to those observed in noncastrated individuals in most patients after withdrawal of ADT for the entire duration of chemotherapy. A similar phenomenon was observed in men with hormone-sensitive prostate cancer, in which approximately half of the patients who received ADT for a long-term remained castrated at 2.5 years after ADT cessation \[[@B17]\]. Results of previous studies indicate that serum testosterone levels remain low after long-term treatment with LHRH agonists \[[@B18][@B19][@B20]\]. Therefore, cessation of LHRH therapy may have only little clinical relevance since serum testosterone levels remain low and may not affect proliferation of cancer cells. However, unlike serum testosterone levels, serum LH levels recover after several weeks to months after cessation of LHRH therapy \[[@B18][@B19][@B20]\]. Cessation of LHRH therapy leads to rapid recovery of LH levels after a median of 58 days to 4.5 months, even after long-term medical castration \[[@B18][@B19]\]. Apart from its action on the testes and adrenal glands, LH acts directly on prostate cancer cells via LH-specific receptors and increases the expression of several key steroidogenic enzymes \[[@B21]\]. Administration of abiraterone alone increases the LH \[[@B22]\]. To date, the SPARE trial ([NCT02077634](http://clinicaltrials.gov/ct2/show/NCT02077634)) is the only trial that provides further insights into the complex hormonal changes that occur after treatment with abiraterone with or without concurrent LHRH therapy \[[@B23]\]. The SPARE trial is investigating the role of continuation of LHRH therapy when starting treatment with abiraterone in patients with asymptomatic or mild symptomatic chemotherapy-naïve CPRC. To date, no study has investigated the efficacy of enzalutamide and concurrent ADT in the treatment of chemotherapy-naïve mCPRC. Therefore, the results of our trial provide important evidence based on unique data.

This study is subject to the usual limitations inherent with retrospective design and data collection. The follow-up period of this study was relatively short. Further, some missing values are another weakness of the data. The rate of AEs in our study was lower than those in the PREVAIL trial, which may be because of the retrospective study design. The advantages of our study are that we analyzed real-world data from multiple institutions. Furthermore, the primary endpoint was OS, which is relatively objective and less confounded even in a retrospective study. Thus, our results provide novel data about the efficacy of enzalutamide and concurrent ADT for the treatment of men with chemotherapy-naïve mCRPC due to the previous medical environment in Korea, in which continuous ADT therapy for mCRPC patients was prohibited.

CONCLUSIONS
===========

A higher proportion of patients in our cohort study showed a GS ≥8 and poor ECOG performance status than those in the PREVAIL study, but the efficacy results in our study were similar to those in the PREVAIL study. Despite the limitations of retrospective studies, the safety was also acceptable. Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC in the real-world setting. Further, compared to enzalutamide alone, concurrent administration of ADT with enzalutamide significantly prolonged the survival. Thus, we recommend concurrent administration of ADT with enzalutamide for the treatment of chemotherapy-naïve patients with mCRPC.
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###### Supplementary Fig. 1

Kaplan--Meier survival curves with 95% confidence interval for (A) overall survival, (B) prostate-specific antigen (PSA) progression free survival and (C) radiographic progression free survival.

![Kaplan--Meier survival curves for (A) overall survival and (B) radiographic progression-free survival in PREVAIL study \[[@B6]\], in PREVAIL Korean *post hoc* analysis \[[@B10]\], and in this study.](icu-61-19-g001){#F1}

![According to concurrent androgen deprivation therapy (ADT), Kaplan--Meier survival estimates for (A) overall survival and (B) time to prostate-specific antigen (PSA) progression-free survival, and (C) radiographic progression-free survival.](icu-61-19-g002){#F2}

![Waterfall plot for prostate-specific antigen (PSA) response according to concurrent androgen deprivation therapy (ADT).](icu-61-19-g003){#F3}

###### Baseline patient and disease characteristics

![](icu-61-19-i001)

  Characteristic                                         PREVAIL (n=1,717) \[[@B6]\]   PREVAIL Korean (n=78) \[[@B10]\]   Current study (n=199)                 
  ------------------------------------------------------ ----------------------------- ---------------------------------- ----------------------- ------------- ------------
  Median age (y)                                         72 (43--93)                   71 (42--93)                        71 (56--83)             67 (42--85)   74 (51-94)
  Median body weight (kg)                                83.1                          82.8                               67.0                    70.5          66.0
  Body mass index (kg/m^2^)                              27.5                          27.5                               24.4                    25.5          24.2
  Gleason score ≥8 at initial diagnosis                  424 (50.6)                    423 (52.4)                         30 (81.1)               31 (81.6)     145 (81.5)
   Missing                                               34                            37                                 3                                     21
  ECOG PS grade=0                                        584 (67.0)                    585 (69.2)                         22 (55.0)               29 (76.3)     62 (33.3)
   Missing                                               13                                                                                                     
  Median PSA (ng/mL)                                     54.1                          44.2                               25.4                    26.2          51.6
  Median LDH (IU/L)                                      185.0                         185.0                              191.0                   184.5         333.0
  Prior radical prostatectomy (%)                        226 (25.9)                    225 (26.6)                         11 (27.5)               4 (10.5)      36 (18.2)
   Missing                                               1                                                                                                      
  Bone disease (%)                                       741 (85.0)                    690 (81.7)                         36 (90.0)               30 (78.9)     160 (82.5)
   Missing                                               5                                                                                                      
  ≥20 bone metastases                                    145 (16.6)                    150 (17.8)                         Unknown                 Unknown       15 (9.9)
   Missing                                               47                                                                                                     
  Soft-tissue disease (lymph node, visceral, or other)   517 (59.3)                    504 (59.6)                         22 (55.0)               22 (57.9)     110 (58.5)
   Missing                                               11                                                                                                     
  Concurrent ADT                                         872 (100.0)                   845 (100.0)                        40 (100.0)              38 (100.0)    89 (44.9)
   Missing                                               1                                                                                                      

Values are presented as median (range), number only, or number (%).

ENZA, enzalutamide; ECOG PS, European Cooperative Oncology Group Performance Status; PSA, prostate-specific antigen; LDH, lactate dehydrogenase; ADT, androgen deprivation therapy.

###### Summary of oncologic outcomes

![](icu-61-19-i002)

  Variable                                 PREVAIL (n=1,717) \[[@B6]\]   PREVAIL Korean (n=78) \[[@B10]\]   Current study (n=199)                 
  ---------------------------------------- ----------------------------- ---------------------------------- ----------------------- ------------- ----------------
  Median time until chemotherapy (mo)      28.0                          10.8                               NYR                     11.2          NYR
   HR (95% CI)                             0.35 (0.30--0.40)             0.21 (0.08--0.51)                                                        
  Median time until PSA progression (mo)   11.2                          2.8                                11.1                    2.9           6.0
   HR (95% CI)                             0.17 (0.15--0.20)             0.31 (0.17--0.56)                                                        
  Median time until first SRE (mo)         31.1                          31.3                               NYR                     20.1          NYR
   HR (95% CI)                             0.72 (0.61--0.84)             1.40 (0.46--4.33)                                                        
  PSA decline of                                                                                                                                  
   ≥50% from baseline (n/total n; %)       666/854 (78.0)                27/777 (3.5)                       28/40 (70.0)            4/38 (10.5)   139/187 (74.3)
   ≥90% from baseline (n/total n; %)       400/854 (46.8)                9/777 (1.2)                        Unknown                 Unknown       88/187 (47.1)

ENZA, enzalutamide; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; SRE, skeletal-related event; NYR, not yet reached.

###### Subsequent anti-neoplastic and endocrine therapies

![](icu-61-19-i003)

  Type of treatment        PREVAIL (n=1,717) \[[@B6]\]   PREVAIL Korean (n=78) \[[@B10]\]   Current study (n=199)               
  ------------------------ ----------------------------- ---------------------------------- ----------------------- ----------- -----------
  Any systemic treatment   382 (43.8)                    642 (76.0)                         7 (17.5)                25 (65.8)   70 (35.2)
  Missing                                                                                                                       23
  Antineoplastic agent     308 (35.3)                    515 (60.9)                         6 (15.0)                22 (57.9)   40 (22.7)
  Docetaxel                286 (32.8)                    479 (56.7)                         5 (12.5)                22 (57.9)   34 (19.3)
  Abiraterone acetate      179 (20.5)                    385 (45.6)                         1 (2.5)                 4 (10.5)    9 (5.1)
  Cabazitaxel              51 (5.8)                      110 (13.0)                         0 (0.0)                 3 (7.9)     2 (1.1)
  Mitoxantrone             5 (0.6)                       9 (1.1)                            0 (0.0)                 1 (2.6)     0 (0.0)

Duplicated count was allowed.

ENZA, enzalutamide.

###### Cox regression analysis for overall survival

![](icu-61-19-i004)

  Variable                                        Univariate   Multivariate                                      
  ----------------------------------------------- ------------ -------------- ------- ----------- -------------- -------
  Age (y)                                                                                                        
   \<65                                           Reference                                                      
   ≥65                                            0.808        0.302--2.162   0.672                              
  ECOG PS                                                                                                        
   0--1                                           Reference                                                      
   ≥2                                             2.993        1.160--7.723   0.023                              
  No. of HT                                                                                                      
   ≤2                                             Reference                                                      
   \>2                                            1.048        0.247--4.453   0.949                              
  Type of progression at study entry                                                                             
   PSA only                                       Reference                                                      
   Radiographic progression +/- PSA progression   0.699        0.350--2.020   0.699                              
  No. of bone lesions                                                                                            
   \<20                                           Reference                                                      
   ≥20                                            1.09         0.141--8.435   0.934                              
  Lymph node involvement                                                                                         
   No                                             Reference                                                      
   Yes                                            0.943        0.415--2.139   0.888                              
  Visceral metastasis                                                                                            
   No                                             Reference                                                      
   Yes                                            1.17         0.342--4.006   0.802                              
  Gleason score                                                                                                  
   ≤7                                             Reference                                                      
   ≥8                                             6.059        0.818--44.86   0.078                              
  Baseline PSA                                                                                                   
   ≤Median                                        Reference                           Reference                  
   \>Median                                       2.517        1.084--5.840   0.032   2.507       0.958--6.563   0.061
  Concurrent ADT                                                                                                 
   No                                             Reference                           Reference                  
   Yes                                            0.335        0.133--0.845   0.02    0.346       0.125--0.958   0.041

HR, hazard ratio; CI, confidence interval; ECOG PS, European Cooperative Oncology Group Performance Status; HT, hormonal treatment; PSA, prostate-specific antigen; ADT, androgen deprivation therapy.

###### Summary of adverse events

![](icu-61-19-i005)

  Parameter                           PREVAIL (n=1,715) \[[@B6]\]   PREVAIL Korean (n=78) \[[@B10]\]   Current study (n=199)               
  ----------------------------------- ----------------------------- ---------------------------------- ----------------------- ----------- -----------
  Median duration of treatment (mo)   16.6                          4.6                                13.0                    5.1         5.0
  Any AEs                             844 (96.9)                    787 (93.2)                         37 (92.5)               30 (78.9)   59 (34.9)
   Missing                                                                                                                                 30
  Serious AEs                         279 (32.0)                    226 (26.8)                         14 (35.0)               3 (7.9)     3 (1.7)
   Missing                                                                                                                                 22
  Grade ≥3 AEs                        374 (42.9)                    313 (37.1)                         13 (32.5)               4 (10.5)    3 (1.8)
   Missing                                                                                                                                 30
  Drug-related grade ≥3 AEs           67 (7.7)                      54 (6.4)                           0 (0.0)                 0 (0.0)     3 (1.7)
   Missing                                                                                                                                 23
  Most common AEs                                                                                                                          
   Musculoskeletal pain               87 (10.0)                     73 (8.6)                           4 (10.0)                2 (5.3)     8 (4.7)
   Fatigue                            310 (35.6)                    218 (25.8)                         8 (20.0)                4 (10.5)    6 (3.6)
   Decreased appetite                 158 (18.1)                    136 (16.1)                         Unknown                 Unknown     5 (3.0)
   Constipation                       193 (22.2)                    145 (17.2)                         6 (15.0)                2 (5.3)     2 (1.2)
   Diarrhea                           142 (16.3)                    119 (14.1)                         Unknown                 Unknown     2 (1.2)
   Hypertension                       117 (13.4)                    35 (4.1)                           Unknown                 Unknown     2 (1.2)
   Hot flush                          157 (18.0)                    65 (7.7)                           5 (12.5)                2 (5.3)     2 (1.2)
   Headache                           91 (10.4)                     59 (7.0)                           Unknown                 Unknown     2 (1.2)
   Back pain                          235 (27.0)                    187 (22.2)                         7 (17.5)                3 (7.9)     1 (0.6)
   Nausea                             201 (23.1)                    190 (22.5)                         6 (15.0)                4 (10.5)    1 (0.6)
   Asthenia                           113 (13.0)                    67 (7.9)                           Unknown                 Unknown     1 (0.6)
   Upper respiratory infection        53 (6.1)                      30 (3.6)                           8 (20.0)                3 (7.9)     0 (0.0)

Values are presented as number only or number (%).

ENZA, enzalutamide; AE, adverse event.
